GVS advice drospirenon-estetrol (Drovelis®)

The National Health Care Institute has completed its marginal assessment whether drospirenon/estetrol (Drovelis®) is interchangeable with a medicine already included in the Medicine Reimbursement System (GVS). The National Health Care Institute recommends including drospirenon/estetrol in List 1A of the Health Insurance Regulation in the 0G03AABO V cluster.

Registered indication

Drospirenon/estetrol (Drovelis®) is an oral contraceptive.

Review of interchangeability

Based on the criteria for interchangeability, it can be concluded that drospirenon/estetrol (Drovelis®) is interchangeable with the other sub-50 single-phase contraceptives that are included in the Medicine Reimbursement System.

The National Health Care Institute's advice

The National Health Care Institute recommends the Minister to include drospirenon/estetrol (Drovelis®) on List 1A in cluster 0G03AABO V of the Medicine Reimbursement System, imposing List 2 conditions. The standard dose of drospirenon/estetrol can be set at 0.86 tablets per day.

List 2 conditions for drospirenon/estetrol (Drovelis®)

The following reimbursement terms for contraceptives (list 2, section 64) are applied.

Condition: solely for an insured person;

  • under 21 years of age;
  • for the treatment of endometriosis if the insured person has been indicated in accordance with the guidelines accepted in the Netherlands by the relevant physicians associations; or
  • for the treatment of menorrhagia associated with anaemia, which means a haemoglobin value lower than the reference values used in the guidelines of the relevant professional associations.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.